Trials / Recruiting
RecruitingNCT03613545
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Efficacy and Safety of Fecal Microbiota Transplantation for Irritable Bowel Syndrome
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Guangzhou First People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. FMT has a higher cure rate than standard antibiotic treatment for recurrent Clostridium difficile infections,and shows promising results in Inflammatory bowel disease(IBD).However, few studies have evaluated whether FMT is effective to treat Irritable bowel syndrome(IBS).The investigators propose to determine the efficiency and safety of FMT in patients with Irritable bowel syndrome.
Detailed description
The present clinical trial aims to re-establish a gut functionality state of intestinal flora through FMT as a therapy for Irritable bowel syndrome(IBS). We established a standard microbiota isolation from donated fresh stool in lab. Then the microbiota is transplanted to the whole colon through a tube. Patients from Guangzhou First People's Hospital in this study will be assigned to receive FMT at least two times according to associated guidelines and follow-up for at least six months. Questionnaires will be used to assess participants at study start and at study completion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | fecal microbiota transplantation | 200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon |
| PROCEDURE | Infusion of sham | Infusion of sham |
| DRUG | probiotics, antibiotics or antidepressants | Drugs such as probiotics, antibiotics, antidepressants |
Timeline
- Start date
- 2018-08-10
- Primary completion
- 2028-12-31
- Completion
- 2030-12-31
- First posted
- 2018-08-03
- Last updated
- 2021-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03613545. Inclusion in this directory is not an endorsement.